

Merck & Co Inc (MRK) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/M1440C3640EEN.html>

Date: April 2021

Pages: 111

Price: US\$ 125.00 (Single User License)

ID: M1440C3640EEN

Abstracts

Merck & Co Inc (MRK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Merck & Co Inc (Merck) is a biopharmaceutical company that discovers, develops, manufactures and markets prescription medicines, biologic therapies, vaccines and animal health products. It offers prescription products for treating cardiovascular, cancer, immune disorders, infectious, respiratory and women's diseases, and diabetes. The company provides animal health products like vaccines, poultry products, livestock products and aquaculture products. Merck sells medicines to drug wholesalers, retailers, hospitals, government agencies and managed health care providers; and animal health products to veterinarians, distributors and animal producers. The company and its subsidiaries operate in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Merck is known as MSD outside the US and Canada and is headquartered in Kenilworth, New Jersey, the US.

Merck & Co Inc Key Recent Developments

Apr 01,2021: Merck Completes Acquisition of Pandion Therapeutics

Mar 30,2021: Merck Announces Acquisition of Alydia Health on behalf of its Planned Spinoff of Organon

Mar 29,2021: Merck to Hold First-Quarter 2021 Sales and Earnings Conference Call on April 29

Mar 24,2021: Merck appoints Caroline Litchfield Chief Financial Officer

Mar 17,2021: M2GEN announces new collaboration with Merck to advance cancer therapies

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Merck & Co Inc - Key Facts
Merck & Co Inc - Key Employees
Merck & Co Inc - Key Employee Biographies
Merck & Co Inc - Major Products and Services
Merck & Co Inc - History
Merck & Co Inc - Company Statement
Merck & Co Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Affiliate
Joint Venture

SECTION 2 – COMPANY ANALYSIS

Company Overview
Merck & Co Inc - Business Description
Business Segment: Animal Health
Overview
Performance
Business Segment: Others
Overview
Performance
Business Segment: Pharmaceutical
Overview
Performance
Geographical Segment: Asia Pacific (other than Japan and China)
Performance
Geographical Segment: China
Performance
Geographical Segment: Europe, Middle East and Africa
Performance
Geographical Segment: Japan
Performance
Geographical Segment: Latin America
Performance

Geographical Segment: Other
Performance
Geographical Segment: The US
Performance
R&D Overview
Merck & Co Inc - Corporate Strategy
Merck & Co Inc - SWOT Analysis
SWOT Analysis - Overview
Merck & Co Inc - Strengths
Merck & Co Inc - Weaknesses
Merck & Co Inc - Opportunities
Merck & Co Inc - Threats
Merck & Co Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES, OIL & GAS FINANCIAL DEALS AND ALLIANCES

Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Merck & Co Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Mar 29, 2021: Merck to Hold First-Quarter 2021 Sales and Earnings Conference Call on April
Mar 24, 2021: Merck appoints Caroline Litchfield Chief Financial Officer
Mar 17, 2021: M2GEN announces new collaboration with Merck to advance cancer therapies
Mar 17, 2021: Mike Nally to leave Merck; Frank Clyburn to lead all Merck human health
Mar 15, 2021: Gilead and Merck announce agreement to jointly develop and

commercialize long-acting, Investigational treatment combinations of Lenacapavir and Islatravir in HIV

Mar 03, 2021: Merck to Present at the Barclays Global Healthcare Conference

Mar 03, 2021: GPHL and Merck build strategic partnership on business innovation and development in GBA

Mar 02, 2021: Merck announces fifth round of global grants to tackle maternal mortality and promote health equity worldwide

Mar 02, 2021: Biden's latest announcement about invoking DPA

Feb 09, 2021: Merck mourns Hans Joachim Langmann

SECTION 6 – APPENDIX

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Merck & Co Inc, Key Facts
Merck & Co Inc, Key Employees
Merck & Co Inc, Key Employee Biographies
Merck & Co Inc, Major Products and Services
Merck & Co Inc, History
Merck & Co Inc, Subsidiaries
Merck & Co Inc, Affiliate
Merck & Co Inc, Joint Venture
Merck & Co Inc, Key Competitors
Merck & Co Inc, Ratios based on current share price
Merck & Co Inc, Annual Ratios
Merck & Co Inc, Annual Ratios (Cont...1)
Merck & Co Inc, Annual Ratios (Cont...2)
Merck & Co Inc, Interim Ratios
Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Merck & Co Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Merck & Co Inc, Performance Chart (2016 - 2020)

Merck & Co Inc, Ratio Charts

Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Merck & Co Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

I would like to order

Product name: Merck & Co Inc (MRK) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/M1440C3640EEN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M1440C3640EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970